Amplia gets nod for new cancer drug trial ahead of US push
Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.
We haven't written up this one. The Age has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.